Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

A webinar in partnership with IAVI.

The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI organized on 23 November 2020 an online event to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention.

The Webinar features an introduction from Mark Feinberg, CEO and President of IAVI, interviewed by Chloe Orkin, Clinical Professor of HIV Medicine at Queen Mary University of London, and chair of the British HIV Association (BHIVA), followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation, and an audience Q&A.

Panel includes:

  • Mike Cohen, Director, Institute for Global Health and Infectious Diseases, UNC School of Medicine, USA.
  • Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, South Africa.
  • Rosemary Mburu, Executive Director WACI Health, Kenya.
  • Erin Sparrow, Technical Officer, Vaccine Product and Delivery Research Immunization, vaccines and Biologicals, World Health Organization, Geneva.
  • Bill Snow,
  • Co-Chair: Hester Kuipers (IAVI) and Roger Tatoud (Enterprise).

The recording of this event is also available in the Enterprise Resources page.

Access to Antibodies, a Global Call to Action

As highlighted in this report published recently by IAVI and Wellcome, the potential of monoclonal antibodies (mAbs) to treat and prevent infectious and neglected diseases is enormous. Yet, with 8 mAb-based products targeting infectious diseases licensed to date, and a rapidly expanding pipeline, most of the world’s population is unlikely to have access to them, unless the global health community takes urgent action to address this inequity.

WP Twitter Auto Publish Powered By : XYZScripts.com